| Sumario: | Simple Summary: Malignant obstruction of the superior vena cava—a crucial vein in the thoracic cavity—is often managed by inserting endovascular stents. While anticoagulation therapy is typically prescribed post procedure, optimal strategies remain undefined. Our retrospective analysis evaluated 49 cancer patients who underwent stenting for this condition. The majority presented with metastatic disease, with a median survival of 2.4 months following intervention. Despite anticoagulation therapy, a significant proportion developed thrombotic complications, either within the stent or systemically. Notably, treatment regimens were frequently modified after discharge, predominantly due to patient preference for oral rather than injectable medications. This evaluation highlights the substantial thrombotic risk these patients face despite therapeutic intervention. The findings underscore the necessity for coordinated multidisciplinary care that prioritizes individualized treatment plans aligned with patient preferences. Further prospective research is warranted to investigate the efficacy of direct oral anticoagulants and to develop tailored risk assessment tools for this specific population. Background/Objectives: A knowledge gap persists regarding anticoagulation therapy after endovascular stent insertion for malignant superior vena cava obstruction (mSVCO). Guidelines are supported by retrospective studies with a radiological focus and lack specific drug recommendations. No studies to date have captured the multi-disciplinary nature of decision-making over time. Methods: This single-center retrospective service evaluation includes patients with solid organ malignancy who received a stent for mSVCO between July 2016 and May 2022. Patient and treatment characteristics, clinical outcomes and prescribing decisions were collected from medical records and analyzed. Results: Of 49 patients (55% female, mean age 59), 73% had metastatic extra-thoracic disease at stent insertion. Technical success was achieved in 98% of cases and 92% survived to discharge. Forty-eight patients were followed until death. Median survival was 2.4 months. Post-procedure imaging (performed in 55% of patients) revealed 10 (21%) cases of systemic venous thromboembolism and 7 cases of stent thrombosis. Forty-four (91%) patients received anticoagulation therapy (62% therapeutic dose low molecular weight heparin). Those with thrombotic complications were fitter pre-procedurally than the rest of the cohort. There was one case of major bleeding. Twenty-two instances of therapy modification occurred following the initial plan, including nine changes due to a patient preference for oral therapy. Conclusion: Patients undergoing stenting for mSVCO demonstrate high thrombotic risk and a poor prognosis. Anticoagulation plans are frequently modified post discharge due to changing risk profiles and patient preferences. Multi-disciplinary collaboration is essential to support patient-centered and individualized management. Future research should investigate direct oral anticoagulants and anti-platelet therapy and develop risk assessment tools for this population.
|
|---|